An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Osimertinib (Primary) ; Fexofenadine
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 Oct 2017 Planned End Date changed from 3 Aug 2017 to 13 Mar 2019.
- 25 Jul 2017 Planned End Date changed from 24 Jul 2017 to 3 Aug 2017.
- 25 Jul 2017 Planned primary completion date changed from 24 Jul 2017 to 3 Aug 2017.